BioLife Solutions, Inc. (BLFS) Given New $7.00 Price Target at Maxim Group
BioLife Solutions, Inc. (NASDAQ:BLFS) had its price objective lifted by Maxim Group from $6.00 to $7.00 in a research note issued to investors on Tuesday morning, Marketbeat.com reports. They currently have a buy rating on the medical equipment provider’s stock.
Separately, Janney Montgomery Scott raised shares of BioLife Solutions from a neutral rating to a buy rating and increased their price target for the company from $2.62 to $5.00 in a research note on Wednesday, July 5th.
BioLife Solutions (NASDAQ BLFS) opened at 5.39 on Tuesday. BioLife Solutions has a 12 month low of $1.43 and a 12 month high of $5.91. The firm’s 50 day moving average price is $4.41 and its 200 day moving average price is $2.88. The stock’s market cap is $71.30 million.
BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). BioLife Solutions had a negative net margin of 63.71% and a negative return on equity of 64.98%. The business had revenue of $2.56 million during the quarter, compared to analysts’ expectations of $2.40 million. On average, equities research analysts predict that BioLife Solutions will post ($0.24) EPS for the current fiscal year.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.